# Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

> **NCT07472972** · — · RECRUITING · sponsor: **University of Zurich** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma
- Lymphoid Hematological Malignancies

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07472972
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472972, "Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07472972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*